Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05026398
Other study ID # FenCog
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 12, 2021
Est. completion date June 22, 2022

Study information

Verified date November 2022
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the investigators will investigate the cognitive effects of fenfluramine, a drug that directly stimulates the release of serotonin in the brain and positively modulates σ1 function. The investigators will use fenfluramine to assess the cognitive effects of modulating serotonin and σ1 function in healthy volunteers using a battery of cognitive tasks that measure learning and memory, executive functioning, reward processing, and emotional processing. The study design is double-blind, and participants will be randomised to either seven days of fenfluramine or placebo administration. All participants will attend two screening visits to assess eligibility. There are two main study visits; during the first, participants will undertake cognitive tasks and questionnaires before taking the initial study dose. One the second study visit, participants will once again complete these tasks and questionnaires after a week of fenfluramine/placebo administration.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date June 22, 2022
Est. primary completion date June 22, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 22 Years
Eligibility Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the research - Not currently taking any medications (except the contraceptive pill) - Aged 18-22 years - Male or female - Sufficiently fluent English to understand and complete the task - Body Mass Index above 18-30 - Weight of 40-75kg Exclusion Criteria: - Current pregnancy (as determined by urine pregnancy test taken during Screening and First Dose Visit) or breast feeding - Any past or current Axis 1 DSM-V psychiatric disorder - Clinically significant abnormal values for liver function tests, clinical chemistry, urine drug screen, blood pressure measurement and ECG. A participant with a clinical abnormality or parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures - History of, or current medical conditions which, in the opinion of the investigator, may interfere with the safety of the participant or the scientific integrity of the study, including epilepsy/seizures, brain injury, hepatic or renal disease, severe gastro-intestinal problems, Central Nervous System (CNS) tumours, neurological conditions - Current or past history of drug or alcohol dependency - Current or past use of 3,4-Methylenedioxymethamphetamine (MDMA) - Use of recreational drugs (e.g. cannabis, cocaine, amphetamines) within past 3 months - Participation in a study which uses the same computer tasks as those in the present study (determined by asking participants about previous studies participated in during screening) - Participation in a study that involves the use of a medication within the last three months - Smoking > 5 cigarettes per day - Typically drinks > 6 caffeinated drinks per day (e.g. tea, coffee, coca cola, Red Bull) - Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fenfluramine
Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
Other:
Placebo
The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution

Locations

Country Name City State
United Kingdom Department of Psychiatry, University of Oxford Oxford

Sponsors (3)

Lead Sponsor Collaborator
University of Oxford National Institute for Health Research, United Kingdom, Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Go/No-Go Task performance Accuracy on the Go/No-Go task Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Primary Change in Auditory Verbal Learning Task Accuracy on AVLT (number of items recalled across blocks) Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Primary Change in N-back task performance Accuracy on the N-back task Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Secondary Changes in reward sensitivity Sensitivity to reward as measured by the Probabilistic Instrumental Learning Task (PILT) Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Secondary Changes in categorisation of emotional words Accuracy to categorise positive and negative descriptor words Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Secondary Changes in recall of emotional words Number of words accurately recalled Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Secondary Changes in recognition of emotional words Number of words accurately recognised Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Secondary Changes in recognition of emotional facial expressions Accuracy of emotion labels (e.g. disgusted face) assigned by participants to expressive faces which have appeared on a computer screen for a period of 500ms. Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Secondary Changes in visual short term memory on the Oxford Memory Test (OMT) Accuracy on the Oxford Memory Task Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Secondary Changes in visual search ability Accuracy during contextual cueing task (CCT) Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
Secondary Changes in control measures of subjective state Ratings on the Positive and Negative Affect Schedule Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
See also
  Status Clinical Trial Phase
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT03708692 - Menstrual Cycle Phases on Recovery and Cognitive Function
Active, not recruiting NCT04505345 - Virtual Reality Cognitive Training in Alcohol Use Disorder N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT02915913 - Effects of Exercise Training on Cognitive Function and Neurotrophic Factors in Overweight Adults N/A
Completed NCT01410097 - Physical and Cognitive Function - Look AHEAD Ancillary Study N/A
Completed NCT03826121 - Efficacy and Safety of Sesame Oil Cake Extract on Improvement of Cognitive Function N/A
Recruiting NCT05621278 - Children to Adults Mental and Psychosomatic Health Study (CAMPS)
Completed NCT05498415 - Feasibility, Acceptability, and Efficacy of the Sleep Move Stand Study N/A
Completed NCT03208569 - Anticholinergic Burden - Treatment Optimization
Completed NCT03793777 - The Effect of Aronia Melanocarpa Extract on Cognitive Function N/A
Recruiting NCT05525299 - Reminiscence-Based Life Review on Copying With Existential Suffering Among Older Cancer Survivors N/A
Completed NCT03698123 - Performance Nutrition for Residents and Fellows N/A
Completed NCT04543500 - Self-regulation of Prefrontal Cortex During Emotional Cognitive Control N/A
Recruiting NCT05891977 - Effect of Tomato Paste Consumption on the Microbiota-gut-brain Axis in Healthy Adults N/A
Recruiting NCT05591885 - Nutrilite Memory Builder on the Improvement of Cognitive Function N/A
Active, not recruiting NCT05575752 - Acute Health Effects of High Temperature Exposure N/A
Completed NCT03716609 - Effects of Magnesium Supplementation on Hemodynamic Parameters and Cognitive Function N/A
Completed NCT02763514 - The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood N/A
Completed NCT02675621 - Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults N/A